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Abstract
Background: The transcription factor MYC is a critical regulator of diverse cellular processes, including both
replication and apoptosis. Differences in MYC-regulated gene expression responsible for such opposing outcomes
in vivo remain obscure. To address this we have examined time-dependent changes in global gene expression in
two transgenic mouse models in which MYC activation, in either skin suprabasal keratinocytes or pancreatic islet b-
cells, promotes tissue expansion or involution, respectively.
Results: Consistent with observed phenotypes, expression of cell cycle genes is increased in both models (albeit
enriched in b-cells), as are those involved in cell growth and metabolism, while expression of genes involved in
cell differentiation is down-regulated. However, in b-cells, which unlike suprabasal keratinocytes undergo
prominent apoptosis from 24 hours, there is up-regulation of genes associated with DNA-damage response and
intrinsic apoptotic pathways, including Atr, Arf, Bax and Cycs. In striking contrast, this is not the case for suprabasal
keratinocytes, where pro-apoptotic genes such as Noxa are down-regulated and key anti-apoptotic pathways (such
as Igf1-Akt) and those promoting angiogenesis are up-regulated. Moreover, dramatic up-regulation of steroid
hormone-regulated Kallikrein serine protease family members in suprabasal keratinocytes alone could further
enhance local Igf1 actions, such as through proteolysis of Igf1 binding proteins.
Conclusions: Activation of MYC causes cell growth, loss of differentiation and cell cycle entry in both b-cells and
suprabasal keratinocytes in vivo. Apoptosis, which is confined to b-cells, may involve a combination of a DNA-
damage response and downstream activation of pro-apoptotic signalling pathways, including Cdc2a and p19Arf/
p53, and downstream targets. Conversely, avoidance of apoptosis in suprabasal keratinocytes may result primarily
from the activation of key anti-apoptotic signalling pathways, particularly Igf1-Akt, and induction of an angiogenic
response, though intrinsic resistance to induction of p19Arf by MYC in suprabasal keratinocytes may contribute.
Background
The c-MYC proto-oncogene encodes a transcription fac-
tor, c-MYC (MYC), which regulates the expression of
cellular targets involved in a wide range of diverse cellu-
lar functions, including cell growth, proliferation, loss of
cell-cell contact, loss of differentiation and angiogenesis
[1-8]. While the predominant role of physiological MYC
in most tissues is to promote G1/S transition in the cell
cycle (and thereby proliferation) [1,9,10] and inhibit dif-
ferentiation [11-13], deregulated MYC (oncogenic) can
lead to uncontrolled proliferation and tumour growth
[3]. Paradoxically though, MYC is able to act as its own
tumour suppressor, as deregulated MYC activity can
also promote apoptosis (both in vitro [14-16] and in
vivo [17]) and senescence [18,19]. See [20] for a recent
review of the MYC field. Such linkage between see-
mingly opposing functions - proliferation and apoptosis
- is also found in other cell-cycle-associated genes, such
as E2f, E1a and c-Fos [21].
The mechanisms by which MYC elicits the vast host
of biological responses for which it appears to be
responsible are not yet fully understood. Currently,
around 1,700 genes have been classified as putative
MYC targets [22,23] using methods such as serial analy-
sis of gene expression (SAGE) [24], DNA microarrays
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[3] and subtractive hybridization [25]. It has been
hypothesized that MYC may have the potential to regu-
late up to 15% of the entire genome [26], leading to it
being described as a ‘master regulator’ of gene
expression.
Regulatable transgenic mouse models have allowed
controlled activation of a modified MYC-containing chi-
maeric transcription factor (MYC-ERTAM) in distinct cell
populations in adult mice, such as the pancreatic islet b-
cells [27] and suprabasal keratinocytes (SBK) of skin epi-
dermis [28]. Our previous work has shown that continu-
ous activation of MYC-ERTAM in these diverse tissues
exposes the dual potential of MYC to activate pathways
involved in cell replication and cell death under differing
environmental conditions. In suprabasal epidermis, MYC
promotes entry of post-mitotic keratinocytes into the cell
cycle, concomitant with loss of differentiation and
increased vascularization leading to formation of pre-
cancerous papillomas [28]. In contrast, although MYC
promotes rapid cell cycle entry of pancreatic b-cells,
these cells quickly proceed to undergo apoptosis leading
to severe cell depletion and diabetes [27]. This indicates a
crucial role for tissue context and the surrounding micro-
environment in determining cell fate.
The divergence of MYC-induced phenotypes between
these two tissues has enabled us to compare MYC-regu-
lated gene expression patterns over a time course of
MYC-ERTAM activation, by employing high-throughput
transcriptome analysis using microarrays. Comparison of
the transcriptional response between the two tissues
identified potential signalling pathways which may pro-
mote apoptosis of b-cells and prevent apoptosis in SBK;
the DNA-damage response pathway, and the Insulin-like
growth factor 1 (Igf1) signalling pathway, respectively. In
addition, up-regulation of angiogenesis-related genes and
of those encoding members of the steroid hormone-regu-
lated Kallikrein serine protease family was found in SBK
but not in b-cells. Kallikreins may increase availability
and action of Igf1 through proteolysis of Igf1 binding
proteins. Together with angiogenesis, Kallikreins may
provide a local tissue-specific regulatory mechanism for
determining ultimate MYC function in vivo.
Results and Discussion
Activation of MYC-ERTAM mediates transcription of genes
involved in a wide range of cellular functions
Time courses were set up following activation of MYC
in b-cells (pancreas) and SBK (skin) via administration
of 4-hydroxytamoxifen (4OHT) for 4 hrs, 8 hrs, 16 hrs
and 32 hrs as described (Methods). Vehicle-treated sam-
ples acted as direct time point controls for 4OHT-trea-
ted samples. Laser capture microdissection (LCM) was
utilized to allow isolation of pancreatic islet tissue. Sig-
nificant gene expression changes for the main
experimental conditions (4OHT treatment, tissue type
and time point following initial treatment) and their
interactions, as well as information on the effects of
further covariates such as batch effects and RNA quality,
were identified using a custom R package, Envisage
(available on request).
Analysis of gene expression for 12,349 curated probe
sets (Methods) identified 6,633 unique genes as being
significantly altered following activation of MYC with a
false discovery rate of 5%. 1,615 genes showed signifi-
cant effects for the joint effects of 4OHT treatment,
time and tissue type; 2,015 genes showed significant
effects for the interaction between 4OHT treatment and
tissue type; 2,221 genes showed significant effects for
the interaction between 4OHT treatment and time; and
1,843 genes showed significant effects for the main
effect of 4OHT treatment only. Of the MYC-responsive
genes, the expression levels of 1,199 were altered greater
than 2-fold (up- or down-regulated) after only 4 hours
of 4OHT treatment for the pancreatic b-cells, while
only 530 were similarly affected for SBK. However, at 8
hours following initial 4OHT treatment, the expression
levels of 1,905 and 1,882 were altered greater than 2-
fold for the pancreas and the skin respectively (Figure
1A). This suggests a more prominent initial response to
MYC in b-cells compared to SBKs.
Gene ontology (GO) enrichment analysis using the
DAVID functional annotation tool [29] identified enrich-
ment of genes involved in myriad cellular functions fol-
lowing activation of MYC. The majority of MYC-
responsive genes were involved in metabolic, transcrip-
tional, transportational and signal transduction pathways
(Figure 1B; green bars). Genes involved in post-transcrip-
tional modification (e.g. RNA processing, RNA splicing)
and post-translational modification (e.g. protein catabolic
process, protein folding, protein localization and ubiqui-
tin-dependent catabolic process) were also significantly
enriched. Similarly, a significant enrichment of genes
relating to ribosome biogenesis was detected, suggestive
of MYC’s recently elucidated role as a regulator of ribo-
some biogenesis and protein synthesis [30]. As expected
given the role of MYC in proliferation, genes involved in
cell cycle progression were amongst the most signifi-
cantly enriched (p = 1.21 × 10-17). Genes involved in
apoptosis and DNA-damage checkpoint pathways were
also enriched (p = 7.81 × 10-3 and p = 5.07 × 10-5 respec-
tively), along with genes involved in related functions
such as cellular response to stress (p = 1.56 × 10-8) and
cytoskeleton organisation (p = 9.12 × 10-5).
Enrichment of GO terms for MYC-responsive genes
showing early changes in expression (≥ 2-fold change
within the first 8 hours of MYC activation) for the pan-
creas (Figure 1B; blue bars) and skin (Figure 1B; red
bars) identified similar numbers for both tissues, with
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the exception of genes relating to DNA-damage and
DNA replication, where a larger number of genes are
detected for the pancreas than for the skin. These
results indicate that whilst expression of genes relating
to multiple cellular functions is common to both tissues,
expression of genes involved in DNA-damage and repli-
cation is more specific to the b-cells.
Expression of putative MYC target genes following MYC-
ERTAM activation
The MYC Target Gene Database [31] currently identi-
fies 1,697 genes as putative MYC targets [22]. Of these,
13.4% and 19.2% were found to be both MYC-respon-
sive and show a 2-fold change in expression in the skin
and pancreas respectively within 8 hours (Additional file
1, Table S1). The predominant role for these genes was
in DNA replication, biosynthesis, metabolism, cell cycle,
cell division and other related functions. Cellular func-
tions relating to apoptosis and cell death were also
highly enriched, although to a lesser degree than those
relating to cellular proliferation. These data suggest that
activation of the MYC-ERTAM protein in vivo leads to a
rapid change in the expression of a large number of
putative MYC targets. However, known target genes
represent only a small fraction of detected MYC-respon-
sive genes, indicating that the majority of these observed
expression changes may be downstream of direct MYC-
induced transcription.
To identify the level of overlap between the genes
classed as significantly altered in this study and those
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Figure 1 Transcriptional response to MYC-ERTAM activation. A) Activation of MYC-ERTAM led to a significant change in expression of a large
number of genes within only 4 hours for the pancreas (≥ 2-fold change, p ≤ 0.05). A similar transcriptional response was not detected until 8
hours post-MYC-ERTAM activation for SBK. B) Analysis of 6,633 genes, whose expression was altered within 8 hours upon activation of MYC-ERTAM
in either pancreas or skin (green bars), identified enrichment of genes in a wide range of MYC-mediated functions. Analyses of genes whose
expression was altered greater than 2-fold within 8 hours for the SBK (red bars) and the pancreatic b-cells (blue bars) showed a similar level of
response to MYC-ERTAM activation in both tissues within 8 hours, with a slight increase in the level of response for the pancreas as compared to
the skin, in particular for DNA-replication and response to DNA-damage. p-values represent significance of enrichment of GO classes for the
6,633 genes. C) Genes identified as showing significant differential expression due to the joint effects of MYC-ERTAM activation and tissue (with or
without an interaction with the time point) were clustered to identify functionally related genes (red, up-regulated; black, no change; green,
down-regulated). The blow-up identifies a group of functionally related genes showing increased expression in SBK but not islet b-cells.
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identified in previous analyses, we utilised the Gene Set
Enrichment Analysis (GSEA) program developed by the
Broad Institute [32]. This allowed us to identify gene
sets in which significant differentially expressed genes
are enriched. Gene sets were taken from the Molecular
Signatures Database (MSigDB), as well as from addi-
tional published datasets. Additional file 1, Table S7 and
Additional file 1, Table S8 show the results from GSEA
(FDR < 0.01) for the genes showing significant expres-
sion at the early time points (4 hours and 8 hours) for
the pancreas and skin, respectively. These results indi-
cate a clear enrichment in the pancreas of genes anno-
tated as being related to MYC function from previous
publications, including MYC target genes from the
MYC Target Gene Database [22], genes indicative of a
MYC-induced oncogenic signature from Blid et al. [33]
and genes up-regulated in the studies of Coller et al.,
Schumacher et al., Yu et al., and Lee et al. [3,34-36].
Similarly, down-regulated genes showed enrichment
with down-regulated genes from the study of Yu et al.
[36]. In comparison, genes up-regulated in the skin are
enriched for genes also found to be up-regulated in the
studies of Coller et al., Yu et al. and Zeller et al.
[3,22,36], while MYC target genes from the MYC Target
Gene Database [22], genes indicative of a MYC-induced
oncogenic signature from Blid et al. [33] were enriched
with an FDR value < 0.017. This suggests that the gene
expression signature identified in both the pancreas and
skin is indicative of changes in expression related to
MYC function.
Cell cycle response following MYC activation
One of the key functions of the MYC onco-protein is
promotion of cell cycle progression, particularly G1/S
phase transition [1,2,37]. Activation of MYC in supraba-
sal keratinocytes (SBK) and pancreatic b-cells has been
previously shown to initiate G1/S transition in target
cells [27,28,38], and this was seen through immunohisto-
logical staining with anti-Ki67 antibodies (Figure 2A), as
well as in the response detected in genes relating to cell
cycle progression by gene ontology classification (Figure
1B and Additional file 1 Table S2). A subset of some
interesting genes from this list is shown in Table 1.
Activation of MYC in the b-cells resulted in a change
in expression of 213 cell cycle- and proliferation-related
genes within 8 hours of MYC activation, with 116 genes
up-regulated and 101 genes down-regulated (Additional
file 1, Table S2). Pcna, a MYC target gene associated
with the cell cycle, was expressed in both pancreatic b-
cells and SBK throughout most of the time-course, with
Cdc25a expressed only in the former. In b-cells, cyclin
genes Ccnd1, Ccnd2 and Ccne2, whose products are
necessary for G1/S-phase transition in the cell cycle,
were up-regulated within 4 hours of MYC activation.
Cyclin genes Ccna2, Ccnb1 and Ccne1, whose products
are involved in later G1/S-phase and G2/M-phase cell
cycle events, were up-regulated greater than 3-fold sub-
sequently at 8 hours (Table 1 and Figure 2C).
Activation of MYC in the SBK resulted in a less pro-
minent cell cycle response compared to b-cells, with a
change in expression of 144 cell cycle- and prolifera-
tion-related transcripts within 8 hours of MYC activa-
tion - 73 genes up-regulated and 74 genes down-
regulated (Additional file 1, Table S2). Of G1/S-phase
cell cycle genes, Ccnd2 and Ccnd3 showed a ≥ 2-fold
increase in expression at 8 hours. In contrast to b-cells,
later cell cycle genes such as Ccna2 and Ccne2 were
either down-regulated or unchanged in SBK. Interest-
ingly, the Ccnb1 gene whose product, cyclin B1, is
involved predominantly in later cell cycle events (G2/M
transition), was down-regulated 2-fold in SBK early in
the time-course. Cyclin B1 interacts with Cdc2a (Cdk1)
to form the mitotic initiation complex, which was also
down-regulated by ~2-fold at 4 hrs in epidermis. This
contrasts with b-cells, in which both Ccnb1 and Cdc2a
showed significant up-regulation. Although speculation
here, these findings may suggest SBK are able to enter
the G1/S phase of the cell cycle, which is a known func-
tion of MYC, but not progress through the G2/M phase.
Interestingly, it was previously shown that over-expres-
sion of MYC causes a P53-dependent G2 arrest in nor-
mal fibroblasts [39]. Such cells may then be enforced by
MYC to reinitiate DNA replication, resulting in
aneuploidy.
Of these cell cycle-related genes, Ccna2 [40] and
Ccnd1 [41,42] have been previously designated as puta-
tive MYC targets through high-throughput screening,
and Ccnb1 [43] and Ccnd2 [44-46] have been previously
confirmed as direct transcriptional targets of MYC
through the use of chromatin Immunoprecipitation
(ChIP) analysis. The cyclin D2-related kinase Cdk4, also
a previously characterized direct MYC target [47],
showed increased expression after 4 hours of MYC acti-
vation in the pancreas, with a 6-fold increase detected
subsequently at 16 hours. Cdk4 was also found to be
highly up-regulated at 8 hours in the skin, with a fold
change of almost 12 (Table 1). No significant change
was detected for the cyclin E-associated CDK gene Cdk2
in either the skin or the pancreas, However Cdk7, which
has a role in both activating cyclin complexes and regu-
lating transcription, was up-regulated at 8 hours in the
skin.
Down-regulation of another known MYC target gene,
the cyclin dependent kinase (CDK) inhibitor Cdkn1b
(p27Kip1), which inhibits G1/S-phase transition by asso-
ciation with the cyclin E-Cdk2 complex [48], was
detected for both the skin and the pancreas. Also, the
expression of Cks2, a MYC target gene whose product is
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Figure 2 Cell cycle following activation of MYC-ERTAM. A) Sections from 4OHT-treated MYC-ERTAM transgenic mice were stained with Ki67-
specific antibodies (green) and a tissue specific antibody (red; insulin for b-cells, keratin 1 for SBK). DAPI staining (blue) identifies cell nuclei. No
Ki67 staining was detected in b-cells or SBK in vehicle-treated samples, although proliferating basal cells in the skin showed clear staining.
Following 32 hours of 4OHT, staining of both b-cells and SBK was detected, indicated by concomitant staining of Ki67 and the tissue-specific
protein. Images shown are representative sections from different levels through replicate tissue samples. b, basal keratinocyte; sb, suprabasal
keratinocyte. B) The change in expression of genes relating to cell cycle following activation of MYC-ERTAM is represented as a heatmap (red, up-
regulated; black, no change; green, down-regulated). Significant change in expression is detected for key early G1-S phase transition genes such
as Ccnd1, Ccnd2 and Ccne2, indicating activation of cell cycle progression, particularly for the pancreas. C) qRT-PCR validation for gene expression
changes in genes relating to cell cycle progression indicated a clear proliferative response in the pancreatic b-cells following MYC-ERTAM
activation. In particular, genes relating to G1/S-phase transition such as Ccnd1, Ccnd2 and Ccne2 showed early changes in expression (8 hours),
whilst genes whose products relate to later cell cycle events such as Ccna2 and Ccnb1 showed increased expression at later time points (32
hours). Few significant changes were detected for these key proliferation markers in SBK. This may be due to the relatively low proportion of
keratinocytes that are responsive to Myc-induced proliferation at these early time-points, whilst differentiated keratinocytes of the granular layer
are refractory to the proliferative influence of MYC.
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Table 1 Cell cycle and cell growth genes responsive to MYC-ERTAM activation
Pancreatic b-Cells Suprabasal Keratinocytes
Gene Symbol RefSeq 4 Hours 8 Hours 16 Hours 32 Hours 4 Hours 8 Hours 16 Hours 32 Hours Myc-response p-value
Cell Cycle
ccna2 X75483 0.96 4.52** 10.49** 3.25** 0.81 0.67 1.39 0.97 2.05E-02
ccna2 X75483 0.55** 1.33* 12.39** 3.47** 0.63** 0.71* 0.99 1.05 1.12E-02
ccnb1 NM_007629 1.02 0.90 2.38** 1.13 0.48** 1.03 1.01 0.58** 9.74E-03
ccnb1 NM_007629 1.06 2.85** 8.15** 3.62** 0.60 0.46* 1.39 0.61 3.73E-02
ccnd1 NM_007631 1.86** 2.09** 0.88 1.45 1.13 1.31 1.79* 1.04 4.55E-02
ccnd1 NM_007631 1.69 2.38 1.41 2.27* 1.05 1.33 1.72 1.26 2.24E-02
ccnd1 NM_007631 3.41** 2.74* 2.03* 2.05 1.35 0.99 1.54 1.81 2.23E-02
ccnd2 NM_009829 1.63* 0.61* 2.28** 2.95** 1.37 1.46 0.94 1.40 2.62E-02
ccnd2 NM_009829 1.82 1.03 1.22 1.90* 0.83 1.33 0.97 1.78 1.48E-02
ccnd2 NM_009829 2.06** 2.04** 1.27 2.30** 0.90 0.84 1.29 0.84 1.21E-02
ccnd2 AK007904 1.99** 0.64* 1.88** 2.62** 1.66* 2.57** 1.00 2.13** 1.28E-03
ccnd2 NM_009829 2.09* 1.00 1.06 2.01* 1.26 0.96 1.12 1.51 2.38E-02
ccnd3 NM_007632 1.26* 0.84 1.54** 1.20 0.81* 2.58** 0.84 3.33** 8.71E-04
ccne1 NM_007633 1.82** 3.37** 7.02** 1.71* 0.94 1.35 1.15 1.82** 2.52E-02
ccne1 BB293079 1.83** 6.68** 1.87** 2.04** 0.85 1.50* 1.16 1.29 1.02E-02
ccne2 AF091432 2.62** 5.86** 5.92** 7.86** 1.74 1.11 1.42 1.39 1.45E-02
cdc2a NM_007659 0.95 2.91** 11.93** 3.35** 0.51* 1.17 0.89 1.12 4.33E-02
cdc25a C76119 2.71** 2.23** 2.09** 3.90** 1.11 0.46** 1.07 0.78 1.84E-03
cdc25a C76119 2.17** 1.73* 2.03** 2.10** 1.02 1.14 1.1 1.21 2.45E-02
cdk4 NM_009870 1.16 0.92 8.41** 1.11 1.32 12.27** 0.74 1.62 2.70E-02
cdk4 NM_009870 1.21 0.74 5.31** 1.5 1.23 11.30** 0.92 1.48 3.31E-02
cdk4 NM_009870 1.20 0.88 5.03** 1.3 1.37 11.17** 0.72 1.37 3.45E-02
cdk7 U11822 0.63* 0.77 3.69** 3.45** 0.82 2.12** 1.09 1.59* 1.37E-02
cks2 NM_025415 0.92 3.03** 10.08** 4.80** 0.51** 0.76 1.27 0.71 4.37E-03
cks2 NM_025415 0.98 2.33** 8.92** 2.34** 0.63* 0.92 0.93 1.32 1.18E-02
pcna BC010343 1 2.44** 17.91** 4.75** 1.32 3.24** 0.76 3.08** 3.38E-02
pcnt NM_008787 2.70** 3.79** 5.22** 4.18** 1.14 1.89** 1.10 1.82** 5.43E-06
Cell Cycle Arrest
cdkn1a AK007630 1.57** 2.05** 1.71** 1.24 0.96 1.44* 0.99 0.90 5.01E-03
cdkn1b NM_009875 1.03 0.19** 0.71 0.95 0.23** 0.42* 0.48* 0.89 1.02E-02
cdkn2a NM_009877 2.17** 1.79** 1.57** 2.61** 1.21 1.07 1.07 0.87 8.43E-03
cdkn2c BC027026 0.32** 1.18 5.62** 0.59* 0.85 1.28 0.87 1.60* 9.38E-03
gadd45g AK007410 0.59* 0.41** 1.88** 0.59** 4.07** 5.16** 3.39** 2.78** 5.95E-03
gas6 NM_019521 0.60** 0.73** 1.02 0.90 1.39** 2.61** 1.43** 5.62** 2.31E-02
ing3 BB298005 0.90 1.12 1.15 0.66** 0.79 0.49** 0.77* 1.34* 1.50E-02
Cell Growth and Cytoskeleton Organization
add1 BF140063 0.99 0.96 1.16 0.96 0.85 2.57** 0.86 3.93** 1.94E-02
add1 BF140063 0.82 0.80 0.62** 0.56** 1.25 2.41** 1.24 0.44** 8.01E-03
cap1 NM_007598 4.88* 0.80 1.16 1.14 1.50 8.59** 0.87 0.17** 4.61E-02
cfl1 NM_007687 1.29 0.51** 1.30 1.89** 1.03 2.28** 1.15 2.14** 4.26E-02
creg1 BC027426 1.06 0.83 2.39** 1.72** 0.82 1.54* 0.69* 1.09 3.57E-02
creg1 BC027426 2.08** 2.12** 1.60** 2.16** 0.69* 0.85 0.98 0.92 3.68E-02
egf NM_010113 1.05 0.79 0.92 1.38* 1.62** 0.47** 0.91 0.84 1.28E-02
lsp1 NM_019391 0.90 0.78* 0.97 1.10 1.02 3.42** 0.67** 1.90** 3.22E-02
myh4 BG794681 0.99 1.25 0.65 1.06 1.72 2.94* 0.94 1.55 8.16E-03
pdlim3 NM_016798 1.00 1.09 1.07 0.78 0.85 2.73** 1.49* 2.29** 4.52E-02
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involved in degradation of p27Kip1, increased from 8
hours following MYC activation in the pancreas. Inter-
estingly, the Cdc2a gene, whose product Cdk1 is essen-
tial for mammalian cell division [49,50], was also found
to be highly up-regulated in b-cells (Table 1). Cdk1 has
been found to substitute for other CDKs to drive cell
cycle progression [51], and is particularly associated
with Cdk4 in G1/S-phase progression [reviewed in 52].
This may indicate a significant role for Cdk1 in the pro-
motion of cell cycle progression following MYC activa-
tion in b-cells. Alternatively, it has been shown that
premature activation of Cdk1 can lead to mitotic cata-
strophe in G2/M-phase and apoptosis (upstream of p53-
induced mitochondrial outer membrane permeabiliza-
tion) in neurons [53]. Given that this CDK was also
detected at later time points, this may indicate a possi-
ble role for Cdk1 in the MYC-induced apoptosis path-
ways. In addition to this, the CDK inhibitor Cdkn2c
(p18Ink4c), which inhibits G1/S-phase transition via inter-
actions with Cdk4 [54] and Cdk6 [55], was down-regu-
lated early in the pancreas. However, by 16 hours
expression levels had risen dramatically, which may be
indicative of cell cycle arrest prior to apoptosis. In addi-
tion, the CDK inhibitor Cdkn1a (p21Cip1) - a down-
stream target of the tumour suppressor p53 - was up-
regulated at 8 hours (Table 1).
Growth arrest specific gene 6 (Gas6) was up-regulated in
SBK (Table 1), and has been found to have different roles
dependant on tissue location, including promotion of cell
cycle progression in fibroblasts and Schwann cells [56,57],
and has been shown to play a role in cellular survival by
inducing signalling through the PI3K/Akt pathway leading
to phosphorylation of the forkhead box protein Foxo1 in
endothelial cells [58] and in oligodendrocytes of the cen-
tral nervous system [59]. Interestingly, the growth arrest
and DNA-damage-inducible 45 gamma gene, Gadd45g, a
proposed MYC target whose product is involved in growth
arrest at the G2/M DNA-damage checkpoint [60], showed
increased expression at 4 hours in SBK, and remained 3-
fold up-regulated throughout the time course, whilst
down-regulation at 8 hours was detected in b-cells. This
suggests potential activation of pathways to limit
unchecked proliferation in the keratinocytes (Table 1).
Genes relating to increased cellular mass, cytoskeleton
organization and DNA replication were also detected for
SBK (Additional file 1, Table S3), including the mem-
brane skeletal proteins Adducin 1 (Add1) and Pdlim3,
the actin-modulating protein Cofilin 1 (Cfl1), members
of the kinesin family of microtubule motor proteins,
members of the myosin superfamily of actin binding
motor proteins (e.g. Myh4, Myoc, Myo1f), and members
of the tubulin family of microtubule proteins (Tuba3a,
Tubb2c, Tubb6). Plectin 1 (Plec1), one of the main com-
ponents of the cytoskeleton, showed an increase in
expression of roughly 3- to 4-fold throughout the early
stages of the time course (Table 1). This increased activ-
ity of microtubule formation and actin formation for
both the pancreas and skin is indicative of increased cel-
lular turnover in both tissues.
Apoptotic response following MYC activation
The ultimate phenotypic response to activation of MYC
in pancreatic b-cells is apoptosis [27]. Immunohistologi-
cal staining for Caspase 3, an early marker for initiation
of apoptosis pathways, indicated an apoptotic response
to MYC activation in the b-cells but not in the SBK
(Figure 3A). In contrast, MYC-activated SBK that have
begun a process of terminal differentiation, re-enter the
cell cycle but are protected from conventional apoptosis
[33,38]. These cells will ultimately be shed and removed
from the surrounding micro-environment thus ridding
the host of potentially harmful pre-cancerous cells [61].
Our array data confirm a large transcriptional response
detected in genes relating to apoptosis and survival by
gene ontology classification in both tissues (Figure 3B
and Additional file 1 Table S4). A subset of important
genes from this list is shown in Table 2.
Activation of MYC in pancreatic b-cells identified a
significant change in expression for 92 genes relating to
cell death and apoptosis. Of these, 42 genes showed an
increase and 50 genes showed a decrease in expression
(Additional file 1, Table S4). Early activation of key reg-
ulators of apoptosis featured prominently in these data.
Activation of MYC in SBK resulted in significant
changes in expression for 66 genes relating to apoptosis
and cell survival, including 37 genes showing an increase
Table 1 Cell cycle and cell growth genes responsive to MYC-ERTAM activation (Continued)
plec1 BM210485 1.31 0.49* 1.25 3.10** 0.53 1.38 1.04 2.87** 2.42E-02
plec1 BM232239 1.20 0.77 1.35 2.46** 3.23** 4.56** 2.82** 0.59* 2.09E-03
tuba3a NM_009446 0.97 0.97 1.13 1.00 0.83 3.09** 0.89 3.20** 1.22E-02
tubb2c BC005547 1.06 1.04 4.72** 1.48* 1.13 2.01** 1.04 1.41* 3.23E-02
tubb6 NM_026473 1.21 0.90 2.95** 1.71* 0.97 2.99** 1.28 3.49** 2.41E-02
Selected MYC-responsive genes relating to cell growth and cell proliferation. ‘MYC-response p-value’ is the p-value identified for the highest-order interaction of
the MYC activation variable and represents the significance of this term within the selected model. Flags represent contrast p-values comparing 4OHT-treated
and vehicle-treated samples at specific time points (’*’, p ≤ 0.05; ‘**’ p ≤ 0.01). Cells are colour-coded based on a detected fold-change greater than 1.5-fold (red,
up-regulated; blue, down-regulated)
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and 29 genes showing a decrease in expression (Addi-
tional file 1, Table S4).
The tumour suppressor Cdkn2a, which encodes for
the CDK inhibitor p16Ink4a and the alternative reading
frame tumour suppressor p19Arf (p14Arf in humans),
was up-regulated 2-fold at 4 hours and remained at an
elevated level throughout the time course for b-cells,
but remained unchanged in SBK (Table 2 and Figure
3C). Previous studies have identified a possible role for
the p19Arf/p53/Mdm2 tumour suppressor pathway in
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Figure 3 Apoptosis following activation of MYC-ERTAM. A) Sections from 4OHT-treated MYC-ERTAM transgenic mice were stained with
Caspase 3-specific antibodies (green) and a tissue specific antibody (red; insulin for b-cells, keratin 1 for SBK). DAPI staining (blue) identifies cell
nuclei. No Caspase 3 staining was detected in b-cells or SBK in vehicle-treated (VT) samples. Following 32 hours of 4OHT, Caspase 3 was
detected in b-cells, but no Caspase 3 activity was detected in treated SBK indicating that apoptosis is specific to the b-cell model. Images shown
are representative sections from different levels through replicate tissue samples. b, basal keratinocyte; sb, suprabasal keratinocyte. B) The change
in expression of genes relating to apoptosis and cell survival following activation of MYC-ERTAM is represented as a heatmap (red, up-regulated;
black, no change; green, down-regulated). C) qRT-PCR validation for gene expression changes in genes relating to apoptosis and cell survival
confirms disparate changes in gene expression between skin and pancreas. Genes relating to DNA-damage in particular, such as Atr and Chk2,
show a clear increase in expression for pancreatic b-cells, which confirms changes seen in microarray data, as did apoptosis genes Cycs and
Endog. As with the microarray data, up-regulation of the Igf1 gene was detected from 8 hours for the skin following MYC-ERTAM activation, with
an increase in expression also detected for the pancreas at the later 32 hour time point.
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Table 2 Apoptosis and cell survival genes responsive to MYC-ERTAM activation
Pancreatic b-Cells Suprabasal Keratinocytes
Gene Symbol RefSeq 4 Hours 8 Hours 16 Hours 32 Hours 4 Hours 8 Hours 16 Hours 32 Hours Myc-response p-value
Apoptosis
bax BC018228 1.09 1.65** 2.49** 1.72** 1.37* 1.70** 1.87** 1.99** 4.61E-02
birc4 BF134200 0.52* 0.64 1.76 1.77* 0.71 0.72 0.77 1.10 3.12E-02
birc4 BF134200 0.69* 0.58* 0.78 0.81 0.53** 0.31** 1.14 0.75 5.29E-03
birc5 BC004702 0.57* 1.99** 16.53** 1.90** 0.61** 1.13 1.06 1.25 8.88E-03
cdc2a NM_007659 0.95 2.91** 11.93** 3.35** 0.51* 1.17 0.89 1.12 4.33E-02
cdkn2a NM_009877 2.17** 1.79** 1.57** 2.61** 1.21 1.07 1.07 0.87 8.43E-03
cflar BE284491 1.03 0.97 1.00 0.94 1.04 1.00 1.28** 2.34** 4.59E-02
cflar BE284491 0.82* 0.87 0.54** 0.43** 1.00 1.13 1.03 1.09 2.22E-02
cflar AK020765 0.78* 0.75* 1.18 0.51** 1.05 1.16 1.01 0.73* 4.40E-02
cycs NM_007808 0.96 0.87 2.54** 2.38** 0.99 1.62** 0.96 0.91 2.84E-02
cycs NM_007808 1.17* 1.98** 1.55** 2.05** 0.83* 1.00 1.17 1.05 1.64E-03
d2wsu81e AV104666 2.85** 2.94** 1.50** 1.85** 0.74* 1.01 0.95 1.24 1.19E-05
endog NM_007931 2.49** 2.90** 2.40** 1.96** 0.75* 1.46** 1.20 1.74** 2.48E-02
fas BG976607 6.55** 6.15** 3.85** 11.34** 0.82 1.22 1.61 1.35 3.79E-02
fas BG976607 3.61** 7.00** 1.13 4.43** 1.33 0.63 1.35 0.46** 6.32E-03
fas BG976607 5.08** 12.85** 5.07** 10.92** 0.72 5.14** 0.74 0.48* 1.12E-03
fas BG976607 2.43** 1.78** 2.28** 2.50** 0.83 1.33 1.09 0.39** 2.21E-03
ing3 BB298005 0.9 1.12 1.15 0.66** 0.79 0.49** 0.77* 1.34* 1.50E-02
pmaip1 NM_021451 1.15 1.13 1.02 0.85 1.33* 0.45** 0.77* 0.87 6.77E-03
tnfrsf12a NM_013749 0.59** 0.85 2.53** 0.72** 1.11 3.15** 1.38** 1.17 4.16E-02
tnfrsf12a NM_013749 0.86 0.87 2.29** 0.85 1.18 2.77** 1.39** 1.11 4.89E-03
tnfrsf4 NM_011659 1.18 0.60* 1.46* 1.64** 1.27 2.12** 1.76** 1.03 5.78E-03
Cell Survival
akt1 NM_009652 1.01 0.97 1.71** 2.31** 0.82 3.23** 0.95 2.29** 4.43E-02
akt2 NM_007434 1.00 1.05 0.98 1.13 1.27 2.21** 1.02 2.26** 7.85E-03
akt2 BC026151 0.78 0.89 2.31** 2.69** 0.99 1.74** 1.01 1.70** 3.97E-02
igf1 NM_010512 2.08* 0.63 0.74 1.20 1.17 2.33** 1.47 2.00* 4.75E-02
igf1 BG075165 0.97 1.11 1.25 2.11** 1.03 1.09 2.34** 3.54** 4.66E-02
igf1 AF440694 1.05 1.00 1.59 3.71** 1.56* 2.24** 1.24 3.08** 4.10E-02
DNA-damage
atm NM_007499 0.84 0.43** 1.12 1.08 0.90 0.92 1.46 0.60* 1.62E-04
atr AF236887 2.25** 3.79** 2.71** 2.76** 1.17 1.17 1.44* 1.53** 3.46E-02
chek1 BB298208 1.10 3.70** 2.35** 1.92** 0.91 1.03 1.31 1.23 4.05E-03
chek1 C85740 1.94* 4.38** 4.71** 4.17** 0.90 0.48* 1.28 1.03 1.62E-02
chek1 NM_007691 1.37 1.79* 3.16** 1.73** 0.74 0.88 1.38 1.33 5.83E-03
chek2 NM_016681 1.24 2.07** 2.65** 2.29** 0.82 0.63* 1.13 1.34 1.98E-02
gadd45g AK007410 0.59* 0.41** 1.88** 0.59** 4.07** 5.16** 3.39** 2.78** 5.95E-03
h2afx NM_010436 1.17 2.17** 4.56** 1.40** 0.67** 1.22* 0.97 1.01 3.43E-03
hus1 NM_008316 0.85 1.97** 2.04** 1.62** 0.97 0.96 1.24 1.23 1.46E-02
hus1 AF076845 1.37 1.05 2.12** 1.29 1.02 1.06 1.07 1.24 1.85E-02
rad1 NM_011232 2.12** 2.27** 2.13* 1.58 0.67 3.18** 0.79 1.94* 3.77E-03
rad51 NM_011234 1.02 6.19** 23.30** 2.40** 0.82 1.12 1.90** 1.46 1.80E-02
Selected MYC-responsive genes relating to apoptosis and cell survival. ‘MYC-response p-value’ is the p-value identified for the highest-order interaction of the
MYC activation variable and represents the significance of this term within the selected model. Flags represent contrast p-values comparing 4OHT-treated and
vehicle-treated samples at specific time points (’*’, p ≤ 0.05; ‘**’ p ≤ 0.01). Cells are colour-coded based on a detected fold-change greater than 1.5-fold (red, up-
regulated; blue, down-regulated).
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MYC-mediated apoptosis [62,63]. Importantly, data
from the Evan lab has elegantly shown that high levels
of MYC-ERTAM activation present in this transgenic
model, led to expression of p19Arf concomitant with
apoptosis [64]. In contrast, low levels of MYC-ERTAM
activation did not induce apoptosis or p19Arf but rather
b-cell proliferation. However, Finch et al. previously
showed that loss of p19Arf in b-cells of the MYC-ERTAM
transgenic model resulted in mainly increased prolifera-
tion, not suppression of apoptosis [65]. Thus the role of
p19Arf in defending against aberrant oncogenic MYC-
induced hyper-proliferation may be related to cell cycle
arrest, and not directly to apoptosis pathways in b-cells.
The anti-apoptotic function of BclxL seen in Rip7-
BclxL/pIns-MYC-ER
TAM (RM) double transgenic mice
indicates that MYC-induced apoptosis is related to the
Bax/Bak-mediated intrinsic mitochondrial pathway
[27,66]. Activation of this intrinsic apoptotic pathway
was evident at the transcriptional level in b-cells by con-
tinued 2-fold increased expression of Bax and the
somatic Cytochrome c gene (Cycs) from 16 hours
onwards after MYC activation, and up-regulation of the
mitochondrial respiratory gene for Endonuclease G,
Endog, after only 4 hours of MYC activation. Both Bax
[67,68] and Cycs [42,69] have been previously shown to
be putative direct MYC targets due to the presence of
non-canonical E-box MYC-Max binding sites, and asso-
ciation of MYC with the Bax promoter has been pre-
viously demonstrated through ChIP [68].
Gene expression profiling of pancreatic b-cells identi-
fied a strong and rapid induction of the DNA-damage
response pathway (Table 2). A large increase in expres-
sion was detected after 8 hours of MYC activation for
Rad51 and H2afx, previously identified MYC targets
whose protein products are involved in homologous
recombination and repair of DNA [70,71]. Also, signifi-
cant up-regulation of Hus1 and Rad1 - whose products
form the 9-1-1 DNA-damage sensing machinery with
Rad9 - indicated that oncogenic stress through deregula-
tion of MYC resulted in the induction of DNA double
strand breaks. The gene for the DNA-damage mediator
Atr was also found to be up-regulated by 2-fold
throughout the time course from 4 hours, and the asso-
ciated checkpoint kinases Chk1 and Chk2 were up-regu-
lated 2-fold from 8 hours (Table 2 and Figure 3C). The
gene for the double-strand break-related DNA-damage
mediator Atm showed 2-fold down-regulation at 8
hours, although it has been shown that Atm plays a sig-
nificant role in MYC-induced apoptosis in lymphoma-
genesis in mice [72]. The genes Cdkn2a (p16/p19Arf)
[2,62] and Atr [73] are previously categorized MYC tar-
get genes. The checkpoint kinase genes Chk1 and Chk2
have not been previously classified as MYC target genes,
indicating that the observed changes in expression may
occur downstream of Atr. Interestingly, as mentioned
previously, expression of Cdkn2c (p18Ink4c), which inhi-
bits Cdk4/6, was significantly up-regulated (6-fold) in b-
cells at 16 hrs. p18Ink4c interacts directly with Atm/Atr
leading to an increase in p53 protein, and promotion of
growth arrest and/or cell death, suggesting a link
between p18 Ink4c and the DNA-damage response path-
ways [74]. Comparatively few DNA-damage related
genes showed significant changes in expression for SBK,
although we cannot exclude the possibility that DNA-
damage proteins may be regulated by MYC through
non-transcriptional means (e.g. protein
phosphorylation).
Of particular interest was the survival factor gene Igf1,
whose product has been shown to inhibit MYC-induced
apoptosis in vitro by blocking Cytochrome c release
from the mitochondria through the Akt1 tumour sup-
pressor pathway [75]. Igf1 was up-regulated throughout
much of the time-course for SBK, and this was con-
firmed using qRT-PCR (Figure 3C). Consistent with this
finding, Akt1 was up-regulated 3-fold at 8 hours and 2-
fold at 32 hours. A similar pattern was observed for
Akt2, a second member of the Akt protein kinase family.
This strongly supports the view that activation of the
Igf-Akt pathway may contribute to suppression of
MYC-related apoptosis. Interestingly, Igf1, Akt1 and
Akt2 were up-regulated at later time points in b-cells. It
is therefore possible that the Igf-Akt pathway is acti-
vated in both tissues, but that the b-cells may be able to
bypass these signals.
The pro-apoptotic Bcl2 family member Pmaip1
(Noxa) and the gene encoding inhibitor of growth pro-
tein p47Ing3 (Ing3) both showed a decrease in expression
of 2-fold at 8 hours in SBK, but exhibited no change in
b-cells (Table 2). Over-expression of p47Ing3 results in
cell cycle arrest and apoptosis in cancer cell lines [76],
and reduced expression and loss of heterozygosity of the
p47Ing3 locus have been found to be associated with
human head and neck squamous carcinomas [77]. Also
seen were several members of the TNF superfamily of
apoptosis-inducing receptors. Tnfrsf12a, which has been
found to be involved in inducing both apoptosis and
angiogenesis [78,79], showed an increase in expression
in the skin of 3-fold at 8 hours. Tnfrsf4, whose product
has been implicated in promoting survival through
induction of Bcl2 and BclXL expression in CD4 T cells
[80], similarly showed an increase in expression of 2-
fold at 8 hours.
A pro-angiogenic response in suprabasal epidermis
The placental growth factor gene, Pgf¸ showed a marked
increase from 8 hours throughout the time course for
the skin (Table 3). In contrast, a 2-fold down-regulation
was detected for the pancreas throughout much of the
Robson et al. BMC Genomics 2011, 12:476
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Table 3 Differentiation, angiogenesis, and cellular adhesion genes responsive to MYC-ERTAM activation
Pancreatic b-Cells Suprabasal Keratinocytes
Gene Symbol RefSeq 4 Hours 8 Hours 16 Hours 32 Hours 4 Hours 8 Hours 16 Hours 32 Hours Myc-response p-value
Differentiation
adamts1 D67076 0.56 0.72 2.12* 1.10 1.42 1.33 3.29** 3.42** 2.89E-02
creg1 BC027426 2.08** 2.12** 1.60** 2.16** 0.69* 0.85 0.98 0.92 3.68E-02
csta C89521 1.12 1.13 1.04 0.88 0.49** 1.04 0.34** 0.52** 1.28E-02
eg666231 C81193 1.26* 1.85** 2.40** 1.98** 0.82* 2.76** 1.19 2.29** 1.94E-02
gck L38990 0.59* 0.14** 2.46** 0.81 1.14 1.41 1.27 1.29 2.31E-03
ins1 NM_008386 0.18* 0.42 9.94** 10.18** 1.55 1.14 1.46 1.26 1.80E-03
ins2 NM_008387 0.17* 0.36 8.70** 12.66** 0.57 1.36 1.00 0.77 1.03E-03
ivl AV009441 0.99 1.24 1.06 1.03 0.35** 0.59** 0.22** 0.82 4.32E-02
krt1 NM_008473 1.49* 0.99 1.17 1.02 0.48** 4.02** 0.70* 0.86 4.05E-02
krt14 BC011074 1.26 1.43* 1.16 0.73* 0.89 2.02** 0.96 0.98 1.93E-02
krt14 BC011074 1.12 1.00 1.16 0.98 0.91 2.17** 0.89 1.04 2.87E-02
mnx1 NM_019944 0.57* 0.40** 0.88 1.40 0.88 1.03 1.06 0.96 1.07E-02
nkx2-2 NM_010919 0.65 0.66* 1.55 0.43** 0.91 0.76 0.97 0.65* 2.22E-02
nkx6-1 AF357883 0.53* 0.32** 2.29** 1.13 0.91 0.94 1.09 0.98 4.29E-02
odc1 S64539 1.72** 2.29** 1.83** 1.82** 1.11 1.62** 0.99 1.81** 2.43E-02
pcnt NM_008787 2.70** 3.79** 5.22** 4.18** 1.14 1.89** 1.1 1.82** 1.37E-02
pcsk2 BB357975 2.24** 0.56* 0.69* 1.08 1.24 1.12 1.04 0.83 1.33E-02
pcsk2 AI839700 0.98 0.48** 0.71** 0.93 1.03 1.08 0.89 0.89 3.31E-02
pcsk2 NM_008792 0.42** 0.39** 1.74** 2.59** 0.94 1.01 1.10 0.96 4.15E-02
pdx1 AK020261 0.74* 0.20** 0.71* 0.47** 1.96** 1.11 1.30 0.95 3.47E-02
pdx1 AK020261 0.60** 0.37** 0.70* 0.62** 1.11 1.08 1.20 0.92 4.14E-02
plec1 BM210485 1.31 0.49* 1.25 3.10** 0.53 1.38 1.04 2.87** 2.42E-02
plec1 BM232239 1.20 0.77 1.35 2.46** 3.23** 4.56** 2.82** 0.59* 2.09E-03
slc2a2 NM_031197 0.84* 0.43** 0.94 0.76** 0.74** 1.00 1.19* 0.91 2.91E-02
sprr1b NM_009265 1.14 1.13 1.10 0.76 0.24** 0.33** 0.67 0.27** 1.27E-02
tgm2 BC016492 1.21 0.74 8.27** 2.63** 0.83 1.89* 2.02** 4.55** 1.54E-03
tgm2 AW321975 1.15 1.47* 3.90** 3.73** 1.09 0.79 1.89** 1.03 1.54E-02
tgm2 BB550124 1.37* 1.36* 3.44** 2.75** 1.26 0.70* 1.91** 1.04 1.58E-02
tgm2 BB041811 1.31* 1.52** 3.05** 3.22** 1.01 0.65** 2.30** 1.22 2.44E-02
Cell Adhesion
itga7 NM_008398 0.85 0.86 1.40* 2.86** 0.50* 1.67* 0.76 2.48** 2.14E-02
itga9 NM_133721 1.16 1.81* 1.14 1.15 0.82 1.45 1.12 2.11** 3.56E-02
itgb2 NM_008404 1.27 1.00 2.18** 3.99** 1.27 2.81** 0.65 4.16** 8.45E-03
itgb3 AV352983 0.83 0.88 1.30* 0.76* 1.12 1.54** 1.94** 2.33** 4.47E-03
itgb6 NM_021359 0.96 0.97 0.95 1.04 1.11 2.22** 1.33** 1.55** 3.45E-02
kl BQ175355 0.81 0.35** 0.92 0.86 1.04 1.09 0.87 0.89 2.13E-02
Immune Response
h2-aa AV086906 3.97* 1.76 0.65 4.15* 0.27* 15.37** 0.48 0.92 6.05E-03
h2-d1 M34962 2.81 2.55* 1.40 5.07** 0.28* 39.62** 0.53 1.31 2.31E-03
h2-l M86502 2.32 1.79 1.83 6.04* 0.24 65.12** 0.8 1.04 5.14E-03
h2-l M69068 2.71 1.98 1.72 6.72** 0.32 48.04** 0.64 0.91 4.38E-02
il1r1 NM_008362 0.53** 0.41** 1.56* 0.62* 0.57** 1.29 1.02 1.33 5.95E-03
il6ra X53802 0.35** 0.45* 0.87 0.42** 1.40 0.77 1.06 0.70 4.70E-03
Angiogenesis
cst7 NM_009977 0.92 0.90 1.22* 1.10 1.04 1.99** 0.95 1.45** 1.79E-02
pgf NM_008827 0.50** 0.39** 1.03 0.43** 1.03 2.29** 2.24** 6.64** 2.52E-02
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time-course. Pgf is a member of the vascular endothelial
growth factor (VEGF) family, and has been shown to
result in increased numbers, branching and size of der-
mal blood vessels following over-expression in basal ker-
atinocytes of adult mice [81]. This may indicate a role in
the development of neovasculature seen following MYC
activation in the SBK [28]. Vegfa, a further member of
the VEGF family important in angiogenesis, was down-
regulated in the pancreas but showed up-regulation in
the skin at 8 hours. In contrast, Vegfc, important in the
growth of lymphatic vessels, showed down-regulation in
the skin at early time points, but was up-regulated
almost 4-fold in the pancreas at the later 32 hour time-
point. Vegfb showed a 2-fold increase from 16 hours in
pancreas compared to no change in the skin. These
results indicate a transcriptional response upon MYC
activation for genes relating to neovascular growth.
Activation of MYC leads to loss of differentiation
Activation of MYC is often associated with loss of dif-
ferentiation of cells and has been found to block term-
inal differentiation in a variety of cell types [11,82,83].
Activation of MYC in the pancreatic b-cells resulted in
down-regulation of Ins1 and Ins2 by > 5-fold at 4 hours,
indicating acute loss of Insulin production within a
short time period following MYC-deregulation. How-
ever, the expression levels of both subsequently
increased dramatically showing almost 10-fold up-regu-
lation from 16 hours (Table 3). Since the islet area used
for RNA extraction was roughly identical for each sam-
ple, this indicates acute increase in the levels of Insulin
production within the b-cells in response to continuous
MYC activation, and not in response to an increase in
b-cell mass. Although perhaps a paradox at first glance,
this response may be the result of a positive feedback
loop due to increased Insulin release into the blood-
stream immediately following MYC activation as we
have previously shown [23]. Observation of transcript
levels of both mRNAs at a later time point (72 hours;
data not shown) indicated that this period of high Insu-
lin production is limited, as gene expression subse-
quently returned to lower levels indicative of loss of b-
cell differentiation. This indicates a short window within
the first two days where a balance is struck between an
increased rate of Insulin production and the simulta-
neous loss of cells due to MYC-driven apoptosis.
Members of the homeodomain transcription factor
family, Pdx1, Pax4, Hb9, Nkx2.2 and Nkx6.1, are essen-
tial in pancreatic development [84]. Probe-sets for the
pancreatic and duodenal homeobox gene Pdx1 (or Ipf1),
whose product activates transcription of the Insulin
gene as well as a number of genes involved in glucose-
sensing [85], showed a significant loss (> 3-fold) in
expression at 8 hours following MYC activation (as well
as potentially significant loss in expression < 2-fold at
all other time points), which correlated with the early
reduction seen in Insulin production (Table 3). The
transcription factor gene Nkx6.1, whose product is
essential for b-cell differentiation [86], also showed sig-
nificant down-regulation in the early stages of MYC
activation, although expression of this gene was shown
to increase during later stages. Further Pdx1-regulated
Table 3 Differentiation, angiogenesis, and cellular adhesion genes responsive to MYC-ERTAM activation (Continued)
vegfa NM_009505 0.83* 0.52** 0.99 0.87 1.19 2.00** 1.16 0.73* 4.27E-02
vegfa U50279 1.16 0.32** 1.12 0.65 0.86 1.79* 1.16 1.02 4.07E-02
vegfb U48800 1.34 1.21 2.29** 2.08** 0.57* 1.72* 0.88 1.33 2.16E-02
vegfc BB089170 1.18 0.69** 0.60** 1.72** 0.76* 0.40** 0.81 0.77* 2.21E-02
vegfc AW228853 1.25 0.70 0.80 3.87** 0.38** 0.51 0.79 1.82 3.87E-02
Extracellular Matrix
klk1 BC010754 0.74 1.44 1.12 1.74 1.95 11.58** 20.38** 244.79** 1.13E-04
klk1 BC010754 1.31 1.36 1.01 1.93 2.72* 16.74** 13.93** 255.71** 4.94E-05
klk21 AB039276 0.63** 0.87 1.24 1.12 1.11 3.36** 4.16** 17.78** 4.06E-07
klk24 NM_010643 0.60* 0.81 1.24 1.15 1.64* 4.99** 12.91** 18.13** 3.33E-06
klk27 NM_020268 0.78 1.03 1.15 1.1 1.55 12.63** 45.42** 128.74** 5.94E-08
klk9 M17962 0.86 1.16 1.18 0.99 1.67 5.97** 9.03** 45.34** 1.11E-04
pgf NM_008827 0.50** 0.39** 1.03 0.43** 1.03 2.29** 2.24** 6.64** 3.14E-02
thbs2 NM_011581 0.98 0.95 1.2 1.00 1.14 1.44** 1.90** 3.92** 2.56E-07
thbs2 BB233297 0.87 1.17 0.83 1.21 2.05** 2.86** 4.37** 3.14** 1.17E-03
thbs2 NM_011581 0.99 0.94 0.99 1.05 2.23** 2.60** 5.86** 3.40** 4.14E-04
Selected MYC-responsive genes relating to differentiation, angiogenesis and cellular adhesion. ‘MYC-response p-value’ is the p-value identified for the highest-
order interaction of the MYC activation variable and represents the significance of this term within the selected model. Flags represent contrast p-values
comparing 4OHT-treated and vehicle-treated samples at specific time points (’*’, p ≤ 0.05; ‘**’ p ≤ 0.01). Cells are colour-coded based on a detected fold-change
greater than 1.5-fold (red, up-regulated; blue, down-regulated).
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genes Slc2a2 (Glut2; previously classed as a putative
MYC target gene) and Gck (Glucokinase), both part of
the glucose-sensing machinery and involved in mem-
brane transport and phosphorylation of glucose respec-
tively, also followed similar expression profiles (Table 3).
Gu et al. identified a group of 217 mature islet-specific
genes [87], 63 of which showed a significant response
following MYC activation in our analysis (Additional file
1, Table S6). The majority of these showed down-regu-
lation at early time points. These data indicate a loss in
b-cell differentiation and carbohydrate metabolism func-
tion following activation of MYC.
Activation of MYC in the SBK resulted in significant
changes in expression of many genes relating to differ-
entiation (Additional file 1, Table S5). In particular, it
was clear that the primary result of MYC activation on
these genes was down-regulation, with 199 differentia-
tion-related genes showing a loss of expression com-
pared to only 112 showing up-regulation. In addition to
these general differentiation markers, activation of MYC
led to down-regulation of several key keratinocyte differ-
entiation genes (Table 3). Most notable was a significant
3-fold decrease in expression for the Involucrin gene,
Ivl, after only 4 hours that was maintained throughout
much of the time course. Involucrin is a key factor in
the progression of differentiation of keratinocytes which
works together with its substrate transglutaminase to
cross-link with membrane proteins and provide support
to the cell [88].
Cornifin (Sprr1b), a precursor to the epidermal corni-
fied envelope, is a further keratinocyte differentiation
markers that has been shown to affect the number of
distinct layers of differentiated keratinocytes [89,90]. As
with Ivl, Sprr1b showed consistently marked down-regu-
lation throughout the time course (Table 3). Similarly,
Cystatin A (Csta), a cysteine protease inhibitor that is
found expressed in keratinocytes as the precursor of the
cornified cell envelope [91,92], showed > 2-fold down-
regulation throughout much of the time course. Up-reg-
ulation of a and b integrin genes such as Itga7, Itga9,
Itgb2, Itgb3 and Itgb6, particularly at later time points,
suggests altered adhesion of SBK with surrounding cells
and the extracellular matrix following MYC activation
(Table 3). Also, expression changes were detected for
several Keratin genes, including up-regulation of the
suprabasal-specific Krt1 and the basal-specific Krt14 at 8
hours (Table 3), which encode fibrous structural pro-
teins in keratinocytes.
Previous findings from the Watt group in which MYC
is targeted to basal keratinocytes has, in contrast, shown
that activation of MYC promotes an increase in the
number of proliferating keratinocytes concomitant with
promotion of terminal differentiation of epidermal stem
cells [89]. In the microarray experiment of Frye et al.
[90], gene expression signatures were compared between
whole skin sections from 4OHT-treated K14-MYC-
ERTAM mice and 4OHT-treated WT mice to identify
cellular networks involved in the promotion of terminal
differentiation of epidermal stem cells at the expense of
hair lineages [90]. Activation of MYC for 4 days was
sufficient to cause hyperproliferation of the interfollicu-
lar epidermis, with increased expression of genes relat-
ing to both proliferation (e.g. Ki67, Krt17, Krt6, Cdc2,
Cdc20) and interfollicular epidermis differentiation
(Filaggrin and Cornifin/Sprp1). In contrast, expression
of genes relating to early G1/S-phase cell cycle progres-
sion are more prominent when MYC is activated in
SBK, whilst keratinocyte-specific differentiation genes
such as Sprp1 generally show down-regulation. This
suggests that activation of MYC suppresses differentia-
tion in keratinocytes already undergoing terminal differ-
entiation (i.e. SBK) to allow proliferation.
In a more recent study, low, intermediate, or high
levels of MYC activity were induced in basal keratino-
cytes, and showed that MYC drives proliferation at all
levels, but at high levels MYC promotes keratinocyte
differentiation [93]. Promotion of differentiation may
therefore act as a fail-safe mechanism against neoplastic
conversion of epidermal stem cells.
The transcriptome fingerprint of MYC activation is varied
in distinct tissues: pancreatic islets and skin
Clustering of genes whose expression changed signifi-
cantly due to the joint effects of MYC activation and
the tissue type identified genes whose expression profiles
were correlated across the time courses for the two tis-
sues, indicating possible co-regulation and functional
similarity. Genes relating to DNA replication, DNA-
damage checkpoint and cell cycle showed tight co-regu-
lation, and showed significantly increased expression in
the pancreatic b-cells. The expression profiles of mini-
chromosome maintenance (MCM) deficient genes
Mcm2, Mcm5, Mcm6 and Mcm7, whose products make
up part of the MCM complex involved in DNA unwind-
ing [94], the Cdt1 gene, whose product is involved in
association of the MCM complex with chromatin, and
various helicase related genes were found to be closely
related, indicated co-expression of genes relating pri-
marily to DNA replication. Close correlation with these
genes was also seen in the pancreas for DNA-damage
checkpoint related genes Atr and Chk1. These genes
showed consistently high levels of expression in the b-
cells, indicating a key role for DNA-damage response
and repair in MYC-induced apoptosis. Conversely, no
significant change was detected for these genes in the
SBK.
In SBK, close correlation was detected for genes
involved in proteolysis, particularly members of the
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Kallikrein family of serine proteases. Expression of Kal-
likrein genes (Klk1, Klk9, Klk21, Klk24 and Klk27) was
found to increase significantly within 8 hours following
activation of MYC, and continued to increase dramati-
cally throughout the time course (Table 3 and Figure
1C). Klk1 and Klk9 have previously been found to be
expressed throughout the epidermis of normal human
skin [95], and play a role in degradation of the extracel-
lular matrix (ECM) and loss of squamous cells during
differentiation. Deregulated expression of Kallikreins has
also been implicated in many cancer types [96-101]. The
mouse Kallikreins Klk21, Klk24 and Klk27 have also
been shown to be functionally active within the testes,
both in degradation of the extra-cellular matrix and
initiation of survival through degradation of Igf1bp3
[102-104]. Kallikrein proteins have been associated with
angiogenesis. Growth of new vasculature is facilitated by
regulating the tissue micro-environment, particularly
through degradation of the extra-cellular matrix often
via activation of matrix metalloproteinases (MMPs).
This indicates a functional relationship between Kallik-
reins and the vascularisation-related gene, placental
growth factor Pgf (a member of the vascular endothelial
growth factor family of angiogenesis-related genes) and
the Thrombospondin 2 gene Thbs2 (an anti-angiogenic
factor which has been linked to extra-cellular matrix
remodelling through modulation of matrix metallopro-
teinases [105]) which showed close correlation with
these genes. Given the prominent angiogenic phenotype
that develops in these pre-cancerous skin lesions follow-
ing MYC activation [33], it is reasonable to speculate
here that Kallikreins and Pgf may be involved.
Conclusions
Deregulation or over-expression of the MYC onco-pro-
tein is a frequent feature of human cancers, which
attests to the pleiotropic role that ectopic MYC plays in
cellular function. However, oncogenic MYC can also
trigger activation of intrinsic tumour suppressor pro-
grams such as p19Arf/p53, which serve to limit propaga-
tion of such harmful cells by inducing growth arrest or
apoptosis. While much is known about the mechanisms
of MYC functions, the pathways responsible for deciding
the ultimate fate of the cell between ‘life’ (uncontrolled
proliferation) and ‘death’ (i.e. apoptosis) in vivo are not
yet clear. The decision for a cell to become apoptotic
depends on the complex interactions of many pro- and
anti-apoptotic factors. Different tissues may exhibit vary-
ing levels of these factors ultimately determining the fate
of a cell. However, tissue-specific environmental charac-
teristics can also affect the interaction between these
factors, having a decisive effect on cell fate. The MYC-
ERTAM transgenic mouse model allows controlled over-
expression of MYC in distinct adult tissues, SBK
(epidermis) and pancreatic b-cells, enabling tracking of
early changes downstream of aberrant MYC activity. In
this study, high-throughput transcriptional profiling was
used to identify transcriptional events that may provide
clues to explain the disparity in the phenotypic response
to MYC activation in SBK (proliferation and survival)
and pancreatic b-cells (proliferation and apoptosis).
Whilst expression of genes relating to multiple cellular
functions (eg. metabolic, transcriptional, transporta-
tional, ribosome biogenesis) is common to both tissues,
expression of genes involved in DNA-damage and repli-
cation is enriched to b-cells. Consistent with early
increased expression of Ki67 in b-cells [27], key G1/S-
phase genes (e.g. those encoding Cyclin D2, Cyclin E
and Cdk4) showed early changes in expression, whilst
G2/M-phase genes (e.g. those encoding Cyclin A and
Cyclin B) showed changes at later time points. Down-
regulation of the cyclin-dependent kinase inhibitor
(CDKI) Cdkn1b (p27Kip1) gene in b-cells was evident as
previously shown in other cell types [48]. The CDKI
Cdkn2c (p18Ink4c), which inhibits Cdk4 and Cdk6, was
also down-regulated, consistent with G1/S phase transi-
tion. The short time period over which these changes
were seen supports the idea that MYC-induced cell
cycle progression occurs through direct activation of key
cell cycle genes such as Ccnd1, Ccnd2 and Ccne2.
In SBK, although there were changes in cell cycle
related genes, the response was much less prominent in
comparison with b-cells. Gene expression changes
included up-regulation of Krt6a, Pcna, Ccnd3, Cdk4,
and the key G1/S phase cyclin gene Ccnd2, accompa-
nied by significant down-regulation of the CDKI gene
Cdkn1b (p27Kip1) throughout the time course. However,
further cell cycle related genes (e.g. Ccna1, Ccne2 and
Cdk2) did not appear to be measurably affected by MYC
activation in SBKs. It is possible that SBK may at some
point struggle to progress through the G2/M phase,
which may be indicated by down-regulation of Ccnb1
and Cdc2a, whose products are essential in later cell
cycle stages. This contrasts with pancreatic b-cells, in
which we found both Ccnb1 and Cdc2a significantly up-
regulated. The less pronounced cell cycle response in
skin may be due to the relatively low proportion of ker-
atinocytes that are responsive to Myc-induced prolifera-
tion at these early time-points. It has previously been
shown that there is only a narrow window when very
early suprabasal cells that have migrated out of the basal
layer, are capable of responding to Myc-induced cell
cycle entry [28,105]. The more differentiated keratino-
cytes of the granular layer are refractory to the prolifera-
tive influence of MYC.
Gene expression profiling of the pancreatic b-cells
identified the DNA-damage checkpoint pathway as a
likely route by which MYC mediates apoptosis in this
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system, leading to downstream activation of p53 and
Bax-mediated release of Cytochrome c from the mito-
chondria. In addition, close correlation was seen in the
pancreas for DNA-damage checkpoint related genes Atr
and Chk1, and members of the MCM complex, Mcm2,
Mcm5 and Mcm7. The change in expression for these
genes following MYC activation was consistently high in
the b-cells, suggesting a key role for DNA-damage
response and repair in MYC-induced apoptosis. Conver-
sely, no significant change was detected for these genes
in the SBK. Recent evidence strongly suggests that
deregulated MYC induces rapid accumulation of DNA-
damage, which is the primary cause of activation of the
Atm/Atr-dependant checkpoint [106,107]. The study of
Dominguez-Sola et al. (2007), in particular, suggests
that the pleiotropic role of MYC is due not only to tran-
scriptional regulation of downstream genes, but also due
to direct interactions with the DNA. This study also
showed that over-expression of MYC results in DNA-
damage and checkpoint activation. Consequently, the
activation of DNA-damage response (DDR) pathways
results in ultimate destruction of the offending cell.
Whilst direct control of these genes by MYC is not dis-
cernible from these data, it is clear that MYC deregulation
induces a transcriptional response representative of cells
undergoing DNA repair, which is a likely explanation for
activation of the intrinsic apoptotic pathway. These results
fit with the hypothesis that deregulated MYC leads to
oncogenic stress and DNA-damage, although whether this
is direct or indirect remains to be seen.
With regard to events downstream of the DDR, we
found an increase in expression of genes associated with
activation of mitochondrial outer membrane permeabili-
sation in pancreatic b-cells. These included the p53-tar-
get Bax, and the pro-apoptotic mitochondrial factors
Cycs and Endog, which may indicate replenishment of
proteins lost from the mitochondria during apoptotic
signalling. In addition, increased expression of the
tumour suppressor Cdkn2a (p19Arf) was also detected,
which may have been involved in stabilization of the
p53 tumour suppressor by inhibition of Mdm2, or in
promoting cell cycle arrest prior to apoptosis together
with up-regulation of the p53-target gene Cdkn1a
(p21Cip1). In contrast, SBK showed no change in these
genes, but instead a decrease in expression of the pro-
apoptotic Bcl2 family member Pmaip1 (Noxa) and the
inhibitor of growth gene Ing3 (p47Ing3). Previous work
has linked over-expression of p47Ing3 with apoptosis
[76], and reduced expression with human head and
neck squamous carcinomas [77]. SBK may be protected
from apoptosis in vivo by the Igf1-Akt survival pathway.
Of particular interest was the early induction of Igf1,
Akt1 and Akt2 in the SBK, and the tight correlation
seen between the three. Expression of these three genes
is also seen at later time points in the pancreas, indicat-
ing that the Igf1-Akt pathway may be activated in both
tissues but is somehow bypassed in the b-cells.
One key difference between the two systems appears
to be the presence of members of the Kallikrein serine
protease family, which were dramatically up-regulated
throughout the time-course for SBK. Kallikrein proteins
have been linked to many forms of cancer, and of parti-
cular note is their role in the Igf1-Akt survival pathway.
Klk1, Klk21, Klk24 and Klk27 have been linked to Igf1-
regulated tumour survival through degradation of the
Igf binding protein Igfbp3 in humans. This prevents
Igfbp3 from antagonizing Igf1-Igf1r interactions, allow-
ing Igf1 to bind to its receptor and initiate survival via
the Akt pathway [102-104,108]. Interestingly, the highest
expression in a similar study from Frye et al. using a
basal keratinocyte model for MYC activation [90] was
for the brain and skin protease gene Bssp1, also known
as Kallikrein 6 (Klk6). This gene remained low in WT
treated mice, but was significantly increased following
MYC expression (129-fold up-regulated). In both mod-
els, MYC activation drives vastly increased Kallikrein
expression, so it is possible that these proteins play simi-
lar roles in cell survival in both systems. Increased
expression of Kallikrein genes in SBK following MYC
activation may therefore create an environment that
favours survival over apoptosis.
In addition to the increased cell proliferation in both
tissues, our data indicate a loss of differentiation in both
pancreatic b-cells and SBK in response to activation of
MYC. In pancreatic b-cells, we found down-regulation of
genes that are essential in pancreatic development, such
as Pdx1 and Nkx6.1, as well as genes involved in glucose-
sensing such as Slc2a2 (Glut2) and Gck, both putative
MYC-targets. In SBK, many significant changes were
detected for genes relating to keratinocyte differentiation
that generally pointed to a loss or delay in differentiation
- an observation that was previously noted in this mouse
model [28]. Interestingly, activation of MYC in the basal
layer of the epidermis actually promotes keratinocyte dif-
ferentiation [93], a mechanism which is thought to pre-
vent epidermal stem cells from becoming cancerous. One
possible explanation for the contrasting behaviour in
suprabasal epidermis, is that SBKs are post-mitotic and
have already entered a terminal differentiation process.
Subsequent activation of MYC in early SBK may promote
loss of differentiation to enable cell cycle entry. Since
MYC-activated SBKs are already migrating upwards
towards the skin surface, they are less likely to pose a
cancer risk to the host given that they will ultimately be
sloughed off as previously shown [28].
We have previously shown that MYC activation in
SBK results in a prominent angiogenic phenotype [28].
From our microarray data, potential candidates that may
Robson et al. BMC Genomics 2011, 12:476
http://www.biomedcentral.com/1471-2164/12/476
Page 15 of 20
promote such a response include Pgf, a member of the
VEGF family, which was highly up-regulated in skin but
in fact down-regulated in pancreas. We also found
Vegfa up-regulated in skin but not in pancreas. Interest-
ingly Vegfc, which is important in growth of lymphatic
vessels, was down-regulated in skin but up-regulated in
pancreas. However, given that prominent angiogenesis is
not detected in the skin until 3-4 days following MYC
activation [28], it is possible that the short time course
considered here is too early to identify a transcriptional
response in all relevant genes relating to vascularisation.
Kallikrein proteins have also been implicated in facilitat-
ing angiogenesis via degradation of the cellular matrix
[109] and our data showed co-regulation of Pgf and Kal-
likrein genes. These data suggest that the local tissue
microenvironment in SBK that promote angiogenic
growth may be linked to survival pathways that protect
the cells against apoptosis.
In summary, activation of MYC results in cell growth,
loss of differentiation and cell cycle entry in both b-cells
and SBK in vivo. Apoptosis, which is confined to b-cells,
involves a combination of a DNA-damage response and
downstream activation of pro-apoptotic signalling path-
ways, including Cdc2a and p19Arf/p53, and downstream
targets. Conversely, avoidance of apoptosis in SBK may
result primarily from the activation of key anti-apoptotic
signalling pathways, particularly those involved in the
Igf1-Akt pathway, and induction of an angiogenic
response (Pgf, Vegfa and Klks). A contributory role for
intrinsic resistance to the induction of DNA-damage
and the p19Arf tumour suppressor pathway by MYC in
SBK is also possible. A possible mechanism whereby tis-
sue-specific environmental factors may influence cell
fate following MYC deregulation has also been pro-
posed, hypothesising that the decision to live or die may
relate to the local tissue-specific microenvironment.
However, this remains speculation as the approach
taken here gives an insight into only one aspect of the
changes occurring within the cell in response to MYC
deregulation. Much remains to be learnt from analysis
of protein-level changes, post-translational modifica-
tions, or epigenetic modifications of DNA. This study
has identified several new lines of investigation for
future analysis into the dual roles of MYC in apoptosis
and survival. It is hoped that such studies will prove
fruitful and provide further insight into the complex
role of this enigmatic protein.
Methods
Tissue Sample Preparation
Transgenic mice expressing switchable pIns-MYC-
ERTAM in pancreatic b-cells or inv-MYC-ERTAM in SBK
have been previously characterized and described
[27,28]. 8-12 week old male mice were treated with
4OHT or vehicle for 4, 8, 16 or 32 hours. Triplicate
samples were collected for each time point for each of
the four conditions; pIns-MYC-ERTAM 4OHT treated/
MYC-ERTAM active ("Panc T”), pIns-MYC-ERTAM vehi-
cle treated/MYC inactive ("Panc U”), Inv-MYC-ERTAM
4OHT treated/MYC active ("Skin T”), Inv-MYC-ERTAM
vehicle treated/MYC inactive ("Skin U”). All mice were
housed and treated in accordance with protocols and
regulations sanctioned by the Home Office under the
Animals Act of 1986.
RNA Isolation and Microarray Hybridization
A modified LCM protocol was devised to preserve RNA
integrity. Fresh frozen pancreas sections were cut to a
thickness of 15 μm, bound to a MMI MembraneSlide
(Molecular Machines and Industries, Rockledge, FL) and
fixed in ice-cold 100% ethanol for 2 mins. Sections were
stained briefly (10 secs) with a 1% Toluidine Blue dye in
100%. Stained sections were dehydrated in 2 changes of
100% ethanol and 2 changes of xylene for 1 minute
each, airdried for 2 minutes and finally left in a vacuum
dessicator for 5 minutes before transportation to the
laser capture platform. The SL μCut LCM system
(Molecular Machines and Industries, Rockledge, FL) was
used to isolate islets of Langerhans from surrounding
exocrine tissue. RNA was collected using the RNA
Microkit protocol (Qiagen, Valencia, CA). The laser cap-
ture procedure was repeated on freshly cut pancreas
sections to collect a total area of islet cells equal to
roughly 1.5 × 106 μm2 for each sample. Due to the thin-
ness of murine suprabasal epidermis, isolation of suffi-
cient good quality RNA for microarray hybridization
from LCM of SBK proved difficult, a problem also
noted by Agar et al. [110]. RNA was instead collected
from 5 fresh frozen skin sections (20 μm) collected
across several levels of the tissue. A modified version of
the Affymetrix GeneChip 2-cycle target labelling in vitro
transcription (IVT) protocol was used, incorporating
double volumes of polyA controls and reagents in the
first round cRNA synthesis stage to increase the yield.
10 μg double-amplified biotin-labelled cRNA were
hybridized to Affymetrix MOE430 2.0 GeneChips (Affy-
metrix, Santa Clara, CA) as described in the Affymetrix
GeneChip Expression Analysis Technical Manual.
Data Analysis
Data were normalized across all samples at the probe-
level using GC-RMA [111]. Analysis of gene expression
data was performed using the Bioconductor microarray
analysis packages in R [112] and GeneSpring GX 7.3.1
(Agilent, Santa Clara, CA). 4OHT-treated samples were
normalized to their respective vehicle-treated counter-
parts to ensure that normalized values corresponded to
the fold-change in gene expression due to activation of
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MYC-ERTAM. Removal of control and non-responsive
probes identified 12,349 probe sets. The custom R pack-
age Envisage was used to identify probe-sets showing
significant differential expression after MYC-ERTAM
activation, across time, and between pancreas and skin
tissue. p-values were calculated for each model term
and their interactions, and were corrected for multiple
testing [113]. Only the highest-order interaction p-value
was considered for genes where the selected model con-
tains multiple terms relating to the MYC-ERTAM activa-
tion state. Contrast p-values were calculated for each
condition by applying an unpaired t-test comparing
4OHT-treated samples with vehicle-treated samples
within each of the 8 groups (4 hrs, 8 hrs, 16 hrs and 32
hrs for skin or pancreas). Significant early-changing (≥
2-fold within 8 hours) probe sets were compared with
known gene-ontologies using the DAVID functional
annotation tool [29]. Quality threshold (QT) partitional
clustering [114] was used to identify genes showing
similar expression profiles, using the Pearson cross-cor-
relation coefficient with a minimum correlation of 0.9
and a minimum cluster size of 14.
Quantitative Real-Time reverse transcriptase PCR
TaqMan qRT-PCR was performed on original total RNA
samples for genes of interest. 20 ng total RNA was
reverse transcribed to cDNA using a high-capacity
cDNA reverse transcription kit (Applied Biosystems,
Foster City, CA). cDNA transcripts were pre-amplified
prior to the qRT-PCR reaction in a multiplexed reaction
using TaqMan preAmp mastermix (Applied Biosystems,
Foster City, CA), with pooled TaqMan qRT-PCR assays
(Applied Biosystems, Foster City, CA) at a concentration
of 0.2X in 1X TE buffer. qRT-PCR was performed using
an ABI Prism 7000 scanner (Applied Biosystems, Foster
City, CA), with an 18s rRNA endogenous control probe
(Applied Biosystems, Foster City, CA). qRT-PCR was
performed for skin and pancreas 4OHT- and vehicle-
treated RNA samples for early time-points 4 hrs and 8
hrs, and for the later 32 hrs time-point. As with micro-
array analysis, quantitative measures of gene expression
upon MYC-activation were calculated by comparing
vehicle- and 4OHT-treated samples directly for each
condition.
Immunohistochemical Staining
Frozen sections were cut to 10 μm and fixed with 4%
paraformaldehyde (PFA) at room temperature (RT) for
10 mins, washed in PBS for 5 mins, and incubated at
RT in a humidifying temperature for 30 mins in 10%
bovine serum albumin (BSA). Pancreas sections were
double stained for Ki67 and insulin, or caspase 3 and
insulin. Sections were incubated at 4°C overnight in pri-
mary antibodies diluted in 1% BSA: Insulin, 1:100
(guinea pig; DAKO, Denmark); Ki67, 1:200, (rabbit;
Novocastra, UK); Caspase 3, 1:200 (rabbit; Cell Signal-
ling Technology Inc., MA). Sections were washed twice
in phosphate-buffered saline (PBS) with 0.1% tween
(PBSt) for 5 mins each and incubated for 30 mins at RT
in a humidifying chamber with secondary antibodies
FITC (Vektor Co., Germany) or ALEXA633 (Invitrogen,
Carlsbad, CA) diluted in 1% BSA (1:200). Skin tissue
sections were sequentially stained for Keratin 1 and
Ki67, or Keratin 1 and Caspase 3. Sections were incu-
bated for 1 hour in Ki67 or Caspase 3 primary antibo-
dies diluted in 1% BSA (1:200). Sections were washed
twice with PBSt for 5 mins each and incubated for 30
mins at RT in a humidifying chamber with FITC anti-
rabbit secondary antibodies diluted in 1% BSA (1:200).
Finally, samples were washed in two changes of PBSt for
5 mins each. This cycle was repeated using Keratin 1
primary antibodies (rabbit; BabCo, CA) diluted in 1%
BSA (1:100) and ALEXA633 anti-rabbit secondary anti-
bodies diluted in 1% BSA (1:200). Slides were mounted
in Vectashield (Vector Labs, Burlingame, CA) mounting
medium containing 4’,6-diamidino-2-phenylindole
(DAPI) and viewed using a Leica Sp2 confocal micro-
scope (Leica, Wetzlar, Germany).
Additional material
Additional file 1: Supplementary gene expression tables and gene
set enrichment analysis results.
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